URGN UroGen Pharma Ltd.

NASDAQ
$41.35

UroGen Pharma Ltd. (URGN) is expected to report earnings on November 12, 2026, before the market open. The consensus earnings estimate is $0.38 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -1.9% since its last earnings release on August 5, 2026.

UroGen Pharma Beat Consensus Estimates
Wednesday, August 5, 2026 · 8:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 12
Thursday · 8:00 AM ET
Earnings Whisper
-
vs $0.38
Rev est $88.64M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $45.58

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About UroGen Pharma Ltd.

UroGen is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.